AstraZeneca PLC (LON:AZN)
London
· Delayed Price · Currency is GBP · Price in GBX 10,412
+20 (0.19%)
Jun 23, 2025, 11:44 AM BST
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B USD in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$54.98B
Revenue Growth
+15.48%
P/S Ratio
3.79
Revenue / Employee
$583.05K
Employees
94,300
Market Cap
161.14B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GSK plc | 31.53B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Indivior | 905.57M |
| Genus | 671.60M |
AstraZeneca News
- 2 days ago - Is the Market Bullish or Bearish on AstraZeneca? - Benzinga
- 6 days ago - Targeted cancer drugs may replace chemo for some patients and drugmakers say they're getting closer - CNBC
- 9 days ago - 5 Ideal 'Safer' Dividend Buys From Bloomberg's June Watch List - Seeking Alpha
- 9 days ago - AstraZeneca in deal with China firm worth up to £4bn - This is Money
- 9 days ago - AstraZeneca Inks China AI Research Deal For Chronic Diseases - NDTV
- 9 days ago - AstraZeneca signs research agreement with China's CSPC - Seeking Alpha
- 9 days ago - AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion - Benzinga
- 9 days ago - AstraZeneca signs $5.2bn deal to develop drugs for chronic disease with Chinese biotech - Financial Times